The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Sulpitac     4-amino-N-[(1- ethylpyrrolidin-2- yl)methyl]...

Synonyms: Deniban, Socian, Solian, Amisulprida, amisulpride, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Aminosultopride


Psychiatry related information on Aminosultopride

  • Moreover, in the studies where depressive symptoms were measured, a significant improvement was also shown in favor of amisulpride [6].
  • Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia [7].
  • Amisulpride showed a shorter response latency than the SSRIs [3].
  • Moreover, its effective alleviation of negative and affective symptoms, its lower association with extrapyramidal symptoms and loss of cognitive function than conventional antipsychotics and its long-term efficacy justifies consideration of the use of higher dosages of amisulpride in this group of patients [8].
  • ). Considering the involvement of delta-opioid receptors in mood regulation, the interaction between amisulpride and RB101 could lead to a new therapeutic approach in the treatment of some mood disorders [9].

High impact information on Aminosultopride

  • RESULTS: Eight amisulpride-treated patients (mean dose=406 mg/day) showed moderate levels of D(2)/D(3) receptor occupancy in the striatum (56%), and significantly higher levels were seen in the thalamus (78%) and temporal cortex (82%) [10].
  • No significant binding of amisulpride to 5-HT2A receptors was detected [11].
  • Low basal prolactin levels predicted improvement of negative symptoms in patients treated with amisulpride [12].
  • While basal TSH secretion was significantly increased by both compounds, TRH-stimulated TSH secretion was elevated only in patients treated with amisulpride [12].
  • D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study [13].

Chemical compound and disease context of Aminosultopride


Biological context of Aminosultopride


Anatomical context of Aminosultopride


Associations of Aminosultopride with other chemical compounds


Gene context of Aminosultopride

  • The SGA amisulpride, however, only binds to D2/D3 receptors, which makes it an interesting tool to test this assumption [31].
  • Both amisulpride doses were significantly more effective than placebo on the primary evaluation criterion (SANS total score, MANOVA P < 0.02) [32].
  • BACKGROUND: Amisulpride is a selective D(2)-D(3) antagonist that has been reported to be effective in the treatment of schizophrenia and major depressive disorder [33].
  • RESULTS: The mean PRL was 1166 (range 499-1892 mIU/l) for a mean amisulpride dose of 406 mg/day (range 150-600 mg/day) [24].
  • To investigate this hypothesis, we tested four atypical antipsychotics, two that are commonly associated with prolactin elevation (amisulpride and risperidone) and two that are less frequently associated (quetiapine and olanzapine) [34].

Analytical, diagnostic and therapeutic context of Aminosultopride


  1. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Engl, J., Laimer, M., Niederwanger, A., Kranebitter, M., Starzinger, M., Pedrini, M.T., Fleischhacker, W.W., Patsch, J.R., Ebenbichler, C.F. Mol. Psychiatry (2005) [Pubmed]
  2. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Sechter, D., Peuskens, J., Fleurot, O., Rein, W., Lecrubier, Y. Neuropsychopharmacology (2002) [Pubmed]
  3. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. Maina, G., Vitalucci, A., Gandolfo, S., Bogetto, F. The Journal of clinical psychiatry. (2002) [Pubmed]
  4. Transient hyperglycemia and decreased glucose tolerance during antipsychotic monotherapy with amisulpride. Opgen-Rhein, C., Neuhaus, A.H., Dettling, M. Journal of clinical psychopharmacology (2007) [Pubmed]
  5. Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome. Atbasoglu, E.C., Ozguven, H.D., Can Saka, M., Goker, C. The Journal of clinical psychiatry. (2004) [Pubmed]
  6. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Storosum, J.G., Elferink, A.J., van Zwieten, B.J., van Strik, R., Hoogendijk, W.J., Broekmans, A.W. Schizophrenia bulletin. (2002) [Pubmed]
  7. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. Müller, M.J., Wetzel, H., Eich, F.X., Rein, W., Puech, A., Benkert, O. Journal of clinical psychopharmacology. (2002) [Pubmed]
  8. Amisulpride: a review of its use in the management of schizophrenia. Curran, M.P., Perry, C.M. Drugs (2001) [Pubmed]
  9. Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment. Cordonnier, L., Sanchez, M., Roques, B.P., Noble, F. Neuroscience (2005) [Pubmed]
  10. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Bressan, R.A., Erlandsson, K., Jones, H.M., Mulligan, R., Flanagan, R.J., Ell, P.J., Pilowsky, L.S. The American journal of psychiatry. (2003) [Pubmed]
  11. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Trichard, C., Paillère-Martinot, M.L., Attar-Levy, D., Recassens, C., Monnet, F., Martinot, J.L. The American journal of psychiatry. (1998) [Pubmed]
  12. Neuroendocrine response to antipsychotics: effects of drug type and gender. Gründer, G., Wetzel, H., Schlösser, R., Anghelescu, I., Hillert, A., Lange, K., Hiemke, C., Benkert, O. Biol. Psychiatry (1999) [Pubmed]
  13. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study. la Fougère, C., Meisenzahl, E., Schmitt, G., Stauss, J., Frodl, T., Tatsch, K., Hahn, K., Möller, H.J., Dresel, S. J. Nucl. Med. (2005) [Pubmed]
  14. Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis. Gentile, S. Drug safety : an international journal of medical toxicology and drug experience. (2006) [Pubmed]
  15. Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. Li, M., Budin, R., Fleming, A.S., Kapur, S. Psychopharmacology (Berl.) (2005) [Pubmed]
  16. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Colonna, L., Saleem, P., Dondey-Nouvel, L., Rein, W. International clinical psychopharmacology. (2000) [Pubmed]
  17. Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect. Marchese, G., Ruiu, S., Casti, P., Bartholini, F., Saba, P., Gessa, G.L., Pani, L. Eur. J. Pharmacol. (2002) [Pubmed]
  18. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Caccia, S. Clinical pharmacokinetics. (2000) [Pubmed]
  19. The rise of body temperature induced by the stimulation of dopamine D1 receptors is increased in acutely reserpinized mice. Vasse, M., Chagraoui, A., Henry, J.P., Protais, P. Eur. J. Pharmacol. (1990) [Pubmed]
  20. Asymptomatic bradycardia associated with amisulpride. Pedrosa Gil, F., Grohmann, R., Rüther, E. Pharmacopsychiatry (2001) [Pubmed]
  21. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. Kasper, S. International clinical psychopharmacology. (2002) [Pubmed]
  22. Metabolic risk during antipsychotic treatment. Newcomer, J.W. Clinical therapeutics. (2004) [Pubmed]
  23. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. Stone, J.M., Bressan, R.A., Erlandsson, K., Ell, P.J., Pilowsky, L.S. Psychopharmacology (Berl.) (2005) [Pubmed]
  24. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Bressan, R.A., Erlandsson, K., Spencer, E.P., Ell, P.J., Pilowsky, L.S. Psychopharmacology (Berl.) (2004) [Pubmed]
  25. From pharmacological profiles to clinical outcomes. Kerwin, R. International clinical psychopharmacology. (2000) [Pubmed]
  26. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Bergemann, N., Kopitz, J., Kress, K.R., Frick, A. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (2004) [Pubmed]
  27. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Xiberas, X., Martinot, J.L., Mallet, L., Artiges, E., Loc'H, C., Mazière, B., Paillère-Martinot, M.L. The British journal of psychiatry : the journal of mental science. (2001) [Pubmed]
  28. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. Xiberas, X., Martinot, J.L., Mallet, L., Artiges, E., Canal, M., Loc'h, C., Mazière, B., Paillère-Martinot, M.L. Journal of clinical psychopharmacology. (2001) [Pubmed]
  29. Use of atypical neuroleptics in child and adolescent psychiatry. Toren, P., Laor, N., Weizman, A. The Journal of clinical psychiatry. (1998) [Pubmed]
  30. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Martinot, J.L., Paillère-Martinot, M.L., Poirier, M.F., Dao-Castellana, M.H., Loc'h, C., Mazière, B. Psychopharmacology (Berl.) (1996) [Pubmed]
  31. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Wagner, M., Quednow, B.B., Westheide, J., Schlaepfer, T.E., Maier, W., Kühn, K.U. Neuropsychopharmacology (2005) [Pubmed]
  32. Treatment of negative symptoms in schizophrenia with amisulpride. Boyer, P., Lecrubier, Y., Puech, A.J., Dewailly, J., Aubin, F. The British journal of psychiatry : the journal of mental science. (1995) [Pubmed]
  33. An open-label study of amisulpride in the treatment of mania. Vieta, E., Ros, S., Goikolea, J.M., Benabarre, A., Popova, E., Comes, M., Capapey, J., Sánchez-Moreno, J. The Journal of clinical psychiatry. (2005) [Pubmed]
  34. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. Kapur, S., Langlois, X., Vinken, P., Megens, A.A., De Coster, R., Andrews, J.S. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  35. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Leucht, S., Pitschel-Walz, G., Engel, R.R., Kissling, W. The American journal of psychiatry. (2002) [Pubmed]
  36. EEG abnormalities under treatment with atypical antipsychotics: effects of olanzapine and amisulpride as compared to haloperidol. Pogarell, O., Juckel, G., Mulert, C., Amann, B., Möller, H.J., Hegerl, U. Pharmacopsychiatry (2004) [Pubmed]
WikiGenes - Universities